Articles By Jack Cush, MD
FDA Hearing on COVID-19 Vaccines
By Jack Cush, MD
23 October 2020
Yesterday the Food and Drug Administration's (FDA) "Vaccines and Related Biological Products Advisory Committee" conve
Read Article
RheumNow Podcast – Back Talk: Questions from Listeners (10.23.20)
By Jack Cush, MD
23 October 2020
Dr. Jack Cush reviews the news, journal reports, survey results and "Back Talk" questions from Rheums.
Read Article
High Burnout Rates Among Rheumatologists
By Jack Cush, MD
22 October 2020
Bergman and colleagues have studied a large cohort of US rheumatologists and found that nearly half meet at least one criterion defining "burnout" among physicians.
Read Article
Remdesivir FDA Approved for Hospitalized COVID-19
By Jack Cush, MD
22 October 2020
The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
Read Article
Clinical Trial Boom or Bust in Severe COVID-19
By Jack Cush, MD
20 October 2020
A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection. Remdesivir
Read Article
Biologic Use for Arthritis Linked With Depression and Anxiety
By Jack Cush, MD
20 October 2020
In a recent study of patients with inflammatory rheumatic diseases, the initiation of a biologic treatment or switching to another biologic was associated with an increased likelihood of the use of antidepressants and anxiolytics, reported Petros P. Sfikakis, MD, of the National and Kapodistrian University of Athens, and colleagues in RMD Open: Rheumatic & Musculoskeletal Diseases.
Read Article
Outpatient Visits Return to Pre-COVID Rates
By Jack Cush, MD
19 October 2020
The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.
Read Article
TNF Inhibitors or non-TNF Biologics - First Best Choice?
By Jack Cush, MD
18 October 2020
Prospective observational findings from the CORRONA registry of rheumatoid arthritis (RA) patients compared clinical outcomes between initial aggressive therapy using either a tumour necrosis factor inhibitor (TNFi) or a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and tar
Read Article
RheumNow Podcast – Good Time Charlie…. (10.16.20)
By Jack Cush, MD
15 October 2020
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
Read Article
Abatacept vs. Upadacitinib in Biologic Refractory Rheumatoid Arthritis
By Jack Cush, MD
15 October 2020
NEJM reports the results of the SELECT-Choice trial, a head to head study of upadacitinib (UPA) and abatacept (ABA) in biologic refractory rheumatoid arthritis (RA); 12 weeks results showed UPA was significantly more clinically effective than ABA using a DAS28-CRP remission, but ABA had fewer safety signals and serious adverse events.
Read Article